BRCA突变携带者卵巢癌后的乳腺癌监测
多机构回顾性图表审查纳入1996至2016年诊断的184例BRCA相关上皮性卵巢癌患者,平均随访80个月。10%在卵巢癌后中位48个月诊断乳腺癌,3年、5年、10年乳腺癌累积发病率分别为5.6%、9.5%、33.3%,作者建议对BRCA携带者进行监测。
要点
- 184例BRCA相关卵巢癌患者中18例(10%)在卵巢癌后中位48个月诊断乳腺癌。
- 乳腺癌3年、5年、10年发病率分别为5.6%、9.5%、33.3%,多数(55%)在卵巢癌后3年诊断。
- 作者建议对BRCA携带者卵巢癌后监测乳腺癌,并主张对卵巢癌患者及时进行基因检测。
核心结论
- 10%的BRCA相关卵巢癌患者在卵巢癌后发生乳腺癌,且发病率随时间增加。
- 作者建议对BRCA携带者卵巢癌后进行乳腺癌监测,因其卵巢癌生存期延长。
- 作者认为对卵巢癌女性及时进行基因检测对于优化乳腺癌筛查资源和治疗分配至关重要。
研究设计与样本
- 多机构回顾性图表审查,纳入1996至2016年诊断的BRCA相关上皮性卵巢癌患者184例,平均随访80个月。
- 排除既往双侧乳房切除者,纳入既往乳腺癌且乳房完整者。
- 采用描述性统计、卡方检验和单变量生存分析。
主要发现
- 18例(10%)在卵巢癌后中位48个月诊断乳腺癌,其中2例(1%)既往乳腺癌者发生对侧乳腺癌,16例(9%)发生原发性乳腺癌。
- 多数乳腺癌(55%)在卵巢癌后3年诊断,3年、5年、10年乳腺癌发病率分别为5.6%、9.5%、33.3%。
- 43%每年进行乳腺X线摄影,34%进行MRI,28例(15%)接受降低风险乳房切除术(RRM)。
- 有无既往乳腺癌的女性之间乳腺癌筛查无统计学显著差异,乳腺癌最常见经乳腺X线摄影发现。
- 3例(17%)在RRM时发现隐匿性乳腺癌,9例(50%)为导管原位癌(DCIS),8例(44%)为I/II期乳腺癌;中位5年和10年生存率分别为68%和43%,组间可比。
临床怎么用
- 作者建议对BRCA携带者卵巢癌后进行乳腺癌监测。
- 作者认为对卵巢癌女性及时进行基因检测至关重要,以更好地分诊乳腺癌筛查资源和治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: BRCA 1 or 2 mutation carriers have increased risk of developing breast cancer (BC) and serous epithelial ovarian cancer (EOC). The incidence of BC over time after EOC is unknown. Optimal BC surveillance for BRCA mutation carriers following EOC has not been defined. METHODS: A multi-institutional retrospective chart review was performed. Patients with BRCA -associated EOC diagnosed between 1996 and 2016 were followed for an average of 80 months. Women with previous bilateral mastectomy were excluded; women with prior BC and an intact breast were included. Descriptive statistics, Chi Square, and univariate survival analysis were performed. RESULTS: 184 patients with BRCA -associated EOC were identified. Eighteen (10%) were diagnosed with BC a median of 48 months following EOC. Two (1%) with prior BC developed contralateral BC and 16 (9%) developed primary BC. The majority of BC (55%) was diagnosed 3 years following EOC. The 3-, 5- and 10-year incidence of BC was 5.6%, 9.5% and 33.3%. Annual mammography was performed in 43% and MRI in 34%. Twenty-eight (15%) women underwent risk-reducing mastectomy (RRM). There was no statistically significant difference in BC screening between women with, and without, a prior BC. BC was most commonly detected on mammogram. Three (17%) women had occult BC at the time of RRM. Nine (50%) had DCIS, and 8 (44%) had stage I/II BC. Median 5- and 10-year survival was 68% and 43% and was comparable between groups. CONCLUSIONS: Ten percent of women developed BC after EOC. The incidence of BC following EOC in BRCA carriers increases over time, and surveillance is recommended given their enhanced survival of EOC. Timely genetic testing for women with EOC is imperative to better triage BC screening resources and treatment.
引用
- John CS, Fong A, Alban R, et al. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers. Gynecol Oncol. 2021. PMID: 34862065. doi:10.1016/j.ygyno.2021.10.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。